SAN RAMON, Calif., June 13, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that Jonathan M. N. Rigby, President and Chief Executive Officer, will present at the 2017 JMP Securities Life Science Conference on Tuesday, June 20, 2017. During the presentation, Mr. Rigby will provide an overview and update on the company's business including the development of its lead drug product candidate Trevyent®, that is in development to treat Pulmonary Arterial Hypertension (PAH).
Date: Tuesday, June 20, 2017
Time: 1:30 pm ET
Location: New York, NY
An audio webcast of the Company’s presentation will be available online at SteadyMed’s website www.steadymed.com. A replay of the presentation will be available for 90 days.
Investors attending the conference who are interested in meeting with Mr. Rigby may request a meeting by contacting their JMP Securities representative, or Lee Roth of The Ruth Group at firstname.lastname@example.org.
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent, a development stage drug product that combines SteadyMed's pre-filled, sterile, single use, disposable, PatchPump® infusion system, with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
Senior Director, Investor Relations and Marketing
The Ruth Group